Innate Pharma appoints Jonathan Dickinson as CEO
The Fly

Innate Pharma appoints Jonathan Dickinson as CEO

Innate Pharma (IPHA) announced that its supervisory board has appointed Jonathan Dickinson as the company’s new CEO and chairman of the executive board, effective November 1. Jonathan Dickinson succeeds Herve Brailly, co-founder of the company, who was interim CEO, during the search process. Jonathan Dickinson most recently served as executive VP and general manager, Europe at Incyte (INCY). Herve Brailly, current interim CEO, will stay for the next few months in an advisory role to ensure a smooth transition. It will be proposed that Brailly joins the board at the next opportunity.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Related Articles
TheFlyWolfe Research starts Incyte at Outperform amid ‘major push’ in I&I
TheFlyIncyte initiated with an Outperform at Wolfe Research
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App